Cisplatin in the modern era: The backbone of first-line chemotherapy for non-small cell lung cancer

Cancer Treatment Reviews

Volumn 44, Issue , 2016, Pages 42-50

  Fennell, D A ^a   Summers, Y ^b   Cadranel, J ^c   Benepal, T ^d   Christoph, D C ^e   Lal, R ^f   Das, M ^g   Maxwell, F ^g   Visseren Grul, C ^g   Ferry, D ^g  

^a UNIVERSITY HOSPITALS OF LEICESTER NHS TRUST   (United Kingdom)

^b CHRISTIE HOSPITAL   (United Kingdom)

^c HÔPITAL TENON   (France)

^d ST GEORGE'S UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^e UNIVERSITY HOSPITAL ESSEN   (Germany)

^f GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^g ELI LILLY AND COMPANY   (United States)

Author keywords

Cisplatin; Doublet regimens; First line; Non small cell lung cancer

Indexed keywords

CISPLATIN; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; DOCETAXEL; GEMCITABINE; PACLITAXEL; TAXOID;

ADVANCED CANCER; CANCER RESISTANCE; CANCER STEM CELL; DNA DAMAGE; DNA REPAIR; DRUG RESEARCH; DRUG RESPONSE; DRUG SAFETY; EXTRACELLULAR MATRIX; GOLGI COMPLEX; HUMAN; HYPOXIA; NEPHROTOXICITY; NEUROTOXICITY; NON SMALL CELL LUNG CANCER; NONHUMAN; PATIENT SELECTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; THROMBOEMBOLISM; TREATMENT OUTCOME; VOMITING; ADENOCARCINOMA; ANALOGS AND DERIVATIVES; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; DRUG DEVELOPMENT; HISTORY; LUNG NEOPLASMS; PATHOLOGY;

ADENOCARCINOMA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; CISPLATIN; DEOXYCYTIDINE; DRUG DISCOVERY; HISTORY, 19TH CENTURY; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; LUNG NEOPLASMS; PACLITAXEL; TAXOIDS;

EID: 84975709018     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2016.01.003     Document Type: Review

References (125)

1. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J Clin 2011, 61:69-90.
2. International Agency for Research on Cancer, World Health Organization. GLOBOCAN 2012: estimated cancer incidence, mortality and prevalence worldwide in 2012. < (Accessed 11 Septembear 2015). http://globocan.iarc.fr/.
3. National Comprehensive Cancer Network. NCCN guidelines: NSCLC (non-small cell lung cancer), V4; 2014 <(Accessed 10 June 2014). http://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf.
4. National Cancer Institute. Non-small cell lung cancer treatment - for health professionals (PDQ®): general information about non-small cell lung cancer (NSCLC); 2014 < (Accessed 10 June 2014). http://www.cancer.gov/cancertopics/pdq/treatment/non-small-cell-lung/healthprofessional.
5. Leal J. The economic burden of cancer across the European Union. Abstract. In: 8th National Cancer Research Institute Conference, Liverpool, UK, 4-7th November 2012 (Accessed 16 August 2013). http://conference.ncri.org.uk/abstracts/2012/abstracts/Para70.html.
6. Turner N.C., Reis-Filho J.S. Genetic heterogeneity and cancer drug resistance. Lancet Oncol 2012, 13:e178-85.
7. Travis W.D., Brambilla B., Riely G. New pathologic classification of lung cancer: relevance for clinical practice and clinical trials. J Clin Oncol 2013, 31:992-1001.
8. Reck M., Popat S., Reinmuth N., De Ruysscher D., Kerr K.M., Peters S., et al. Metastatic non-small-cell lung cancer (NSCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2014, 25(Suppl 3):iii27-39.
9. Kumar V., Abbas A.K., Aster J.C. Robbins basic pathology 2013, Elsevier Saunders, Philadelphia (PA), p. 212, Chapter 5, ISBN 978-1-4377-1781-1785. 9th ed.
10. Shaw A.T., Kim D.W., Nakagawa K., et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 2013, 368:2385-2394.
11. Ardizzoni A., Boni L., Tiseo M., et al. Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small cell lung cancer: an individual patient data meta-analysis. J Natl Cancer Inst 2007, 99:847-857.
12. Peyrone M. Ueber die Einwirkung des Ammoniaks auf Platinchlorür. Ann Chem Pharm 1844, 51:1-29.
13. Rosenberg B., Vancamp L., Krigas T. Inhibition of cell division in Escherichia coli by electrolysis products from a platinum electrode. Nature 1965, 205:698-699.
14. Rosenberg B., Van Camp L., Trosko J.E., Mansour V.H. Platinum compounds: a new class of potent antitumour agents. Nature 1969, 222:385-386.
15. Einhorn L.H. Treatment of testicular cancer: a new and improved model. J Clin Oncol 1990, 8:1777-1781.
16. Wiltshaw E., Subramarian S., Alexopoulos C., Barker G.H. Cancer of the ovary: a summary of experience with cis-dichloradiammineplatinum(II) at the Royal Marsden Hospital. Cancer Treat Rep 1979, 63:1545-1548.
17. Gralla R.J., Casper E.S., Kelsen D.P., et al. Cisplatin and vindesine combination chemotherapy for advanced carcinoma of the lung: a randomized trial investigating two dosage schedules. Ann Int Med 1981, 95:414-420.
18. Alderden R.A., Hall M.D., Hambley T.W. The discovery and development of cisplatin. J Chem Educ 2006, 83:728-734.
19. Carpenter D.P. Reputation and power: organizational image and pharmaceutical regulation at the FDA 2010, Princeton University Press, Princeton, NJ.
20. Cvitkovic E., Spaulding J., Bethune V., Martin J., Whitmore W.F., et al. Improvement of cis-dichlorodiammineplatinum (NSC 119875): therapeutic index in an animal model. Cancer 1977, 39:1357-1361.
21. Rajeswaran A., Trojan A., Burnand B., Gianelli M. Efficacy and side effects of cisplatin- and carboplatin-based doublet regimens versus non-platinum-based regimens as first-line treatment of metastatic non-small cell carcinoma: a systematic review of randomized controlled trials. Lung Cancer 2008, 59:1-11.
22. Ihde D.E. Chemotherapy of lung cancer. N Engl J Med 1992, 327:1434-1441.
23. Johnson D.H. Evolution of cisplatin-based chemotherapy in non-small cell lung cancer: a historical perspective and the Eastern Coopertative Oncology Group experience. Chest 2000, 117(4 Suppl 1):133S-137S.
24. Non-small Cell Lung Cancer Collaborative Group Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials. BMJ 1995, 311:899-909.
25. Cullen M.H., Billingham M.J., Woodroffe C.M., et al. Mitomycin, ifosfamide and cisplatin in unresectable non-small cell lung cancer: effects on survival and quality of life. J Clin Oncol 1999, 17:3188-3194.
26. Thongprasert S., Sanguanmitra P., Juthapan W., Clinch J. Relationship between quality of life and clinical outcomes in advanced non-small cell lung cancer: best supportive care (BSC) versus BSC plus chemotherapy. Lung Cancer 1999, 24:17-24.
27. Helsing M., Bergman B., Thaning L., Hero U. Quality of life and survival in patients with advanced non-small cell lung cancer receiving supportive care plus chemotherapy with carboplatin and etoposide or supportive care only. A multicentre randomised phase III trial. Eur J Cancer 1998, 34:1036-1044. Joint Lung Cancer Group.
28. Schiller J.H., Harrington D., Belani C.P., et al. Comparison of four chemotherapy regimens for advanced non-small cell lung cancer. N Engl J Med 2002, 346:92-98.
29. Scagliotti G.V., Parikh P., von Pawel J., et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced stage non-small cell lung cancer. J Clin Oncol 2008, 26:3543-3551.
30. 2 (GC80) vs carboplatin AUC 6 (GCb6) in advanced NSCLC. Thorax 2011, 66(Suppl 4):A41. Abstract S85.
31. Azzoli C.G., Temin S., Aliff T., et al. 2011 focused update of 2009 American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small cell lung cancer. J Clin Oncol 2011, 29:3825-3831.
32. Gridelli C., Ardizzoni A., Le Chevalier T., et al. Treatment of advanced non-small cell lung cancer patients with ECOG performance status 2: results of an European Experts Panel. Ann Oncol 2004, 15:419-426.
33. Lilenbaum R., Villaflor V.M., Langer C., et al. Single-agent versus combination chemotherapy in patients with advanced non-small cell lung cancer and a performance status of 2: prognostic factors and treatment selection based on two large randomized clinical trials. J Thorac Oncol 2009, 4:869-874.
34. Zukin M., Barrios C.H., Pereira J.R., et al. Randomized phase III trial of single agent pemetrexed versus carboplatin plus pemetrexed in patients with advanced non-small cell lung cancer and Eastern Cooperative Oncology Group Performance status of 2. J Clin Oncol 2013, 31:2849-2853.
35. Quoix E., Zalcman G., Oster J.P., et al. Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small cell lung cancer: IFTC-0501 randomised, phase 3 trial. Lancet 2011, 378:1079-1088.
36. Smit E., Moro-Sibilot D., de Castro Carpeño J., et al. Analysis of patients treated with cisplatin or carboplatin-based doublet chemotherapy in the European FRAME observational study. Ann Oncol 2014, 25(Suppl 4):iv426-470.
37. Rossi A., Chiodini P., Sun J.-M., et al. Six versus fewer planned cyclesof first-line platinum-based chemotherapy for non-small cell lung cancer: a systematic review and meta-analysis of individual patient data. Lancet Oncol. 2014, 15(11):1254-1262. 10.1016/S1470-2045(14)70402-4.
38. 2) for patients with lung cancer: a prospective study. Jpn J Clin Oncol 2013, 43:1105-1109.
39. Hotta K., Takigawa N., Hisamoto-Sato A., et al. Reappraisal of short-term low-volume hydration in cisplatin-based chemotherapy: results of a prospective feasibility study in advanced lung cancer in the Okayama Lung Cancer Study Group Trial 1002. Jpn J Clin Oncol 2013, 43:1115-1123.
40. Sekine I., Kubota K., Tamura Y., et al. Innovator and generic cisplatin formulations: comparison of renal toxicity. Cancer Sci 2011, 102:162-165.
41. Niho S., Yamanaka T., Umemura S., et al. Renal toxicity caused by brand-name versus generic cisplatin: a comparative analysis. Jpn J Clin Oncol 2013, 43:390-395.
42. Ochi N., Yamane H., Hotta K., et al. Cisplatin-induced hyponatremia in malignancy: compariuson between brand-name and generic formulation. Drug Des Devel Ther 2014, 8:2401-2408.
43. Marty M., Pouillart P., Scholl S., et al. Comparison of the 5-hydroxytryptamine3 (serotonin) antagonist ondansetron (GR 38032F) with high-dose metoclopramide in the control of cisplatin-induced emesis. N Engl J Med 1990, 322:816-821.
44. Italian Group for Antiemetic Research Ondansetron + dexamethasone vs metoclopramide + diphenhydramine in prevention of cisplatin-induced emesis. Lancet 1992, 340:96-99.
45. Hesketh P.J., Grunberg S.M., Gralla R.J., Aprepitant Protocol 052 Study Group, et al. The oral neurokin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin - the Aprepitant Protocol 052 Study Group. J Clin Oncol 2003, 21:4112-4119.
46. Roila F., Herrstedt J., Aapro M., et al. Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol 2010, 21(Suppl 5):v232-243.
47. Grunberg S., Chua D., Maru A., et al. Single-dose fosapreptitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol-EASE. J Clin Oncol 2011, 29:1495-1501.
48. McWhinney S.R., Goldberg R.M., McLeod H.L. Platinum neurotoxicity pharmacogenetics. Mol Cancer Ther 2009, 8:10-16.
49. Siegal T., Haim N. Cisplatin-induced peripheral neuropathy. Frequent off-therapy deterioration, demyelinating syndromes, and muscle cramps. Cancer 1990, 66:1117-1123.
50. Rademaker-Lakhai J.M., Crul M., Zuur L., et al. Relationship between cisplatin administration and the development of ototoxicity. J Clin Oncol 2006, 24:918-924.
51. Knight K.R., Kraemer D.F., Neuwelt D.A. Ototoxicity in children receiving platinum chemotherapy: under-estimating a commonly occurring toxicity that may influence academic and social development. J Clin Oncol 2005, 23(34):8588-8596.
52. Wolf S., Barton D., Kottschade L., Grothey A., Loprinzi C. Chemotherapy-induced peripheral neuropathy: prevention and treatment strategies. Eur J Cancer 2008, 44:1507-1515.
53. Amptoulach S., Tsavaris N. Neurotoxicity caused by the treatment with platinum analogues. Chemother Res Pract 2011, 2011:843019. 10.1155/2011/843019.
54. Travis L.B., Fossa T.D., Sesso H.D., et al. Chemotherapy-induced peripheral neurotoxicity and ototoxicity: new paradigms for translational genomics. J Natl Cancer Inst 2014, 106. pii.
55. Heit J.A., Silverstein M.D., Mohr D.N., Petterson T.M., O'Fallon W.M., Melton L.J. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Int Med 2000, 160:809-815.
56. Numico G., Garrone O., Dongiovanni V., et al. Prospective evaluation of major vascular events in patients with nonsmall cell lung carcinoma treated with cisplatin and gemcitabine. Cancer 2005, 103:994-999.
57. Licciardello J.T.W., Moake J.L., Rudy C.K., Karp D.D., Hong W.K. Elevated plasma von Willebrand factor levels and arterial occlusive complications associated with cisplatin-based chemotherapy. Oncology 1985, 42:296-300.
58. Doll D.C., Ringenberg Q.S., Yarbro J.W. Vascular toxicity associated with antineoplastic agents. J Clin Oncol 1986, 4:1405-1417.
59. Lechner D., Kollars M., Gleiss A., Kyrle P.A., Weltermann A. Chemotherapy-induced thrombin generation via procoagulant endothelial microparticles is independent of tissue factor activity. J Thromb Haemost 2007, 5:2445-2452.
60. Moore R.A., Adel N., Riedel E., et al. High incidence of thromboembolic events in patients treated with cisplatin-based chemotherapy: a large retrospective analysis. J Clin Oncol 2011, 29:3466-3473.
61. Depierre A., Milleron B., Moro-Sibilot D., et al. Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage I (except T1N0), II, and IIIa non-small-cell lung cancer. J Clin Oncol 2002, 20:247-253.
62. Chang A. Chemotherapy, chemoresistance and the changing treatment landscape for NSCLC. Lung Cancer 2011, 71:3-10.
63. Kelland L. The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer 2007, 7:573-584.
64. Sinani D., Adle D.J., Kim H., Lee J. Distinct mechanisms for Ctr1-mediated copper and cisplatin transport. J Biol Chem 2007, 282:26775-26785.
65. Quinn J.E., James C.R., Stewart G.E., et al. BRCA1 mRNA expression levels predict for overall survival in ovarian cancer after chemotherapy. Clin Cancer Res 2007, 13:7413-7420.
66. Font A., Taron M., Gago J.L., et al. BRCA1 mRNA expression and outcome to neoadjuvant cisplatin-based chemotherapy in bladder cancer. Ann Oncol 2011, 22:139-144.
67. Bunting S.F., Callen E., Wong N., et al. 53BP1 inhibits homologous recombination in Brca1-deficient cells by blocking resection of DNA breaks. Cell 2010, 141:243-254.
68. Bonanno L., Costa C., Majem M., et al. The predictive value of 53BP1 and BRCA1 mRNA expression in advanced non-small-cell lung cancer patients treated with first-line platinum-based chemotherapy. Oncotarget 2013, 4:1572-1581.
69. Vanhecke E., Valent A., Tang X., et al. 19q13-ERCC1 gene copy number increase in non-small-cell lung cancer. Clin Lung Cancer 2013, 14:549-557.
70. Olaussen K.A., Dunant A., Fouret P., et al. DNA Repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 2006, 355:983-991.
71. Friboulet L., Olaussen K.A., Pignon J.P., et al. ERCC1 isoform expression and DNA repair in non-small cell lung cancer. N Engl J Med 2013, 368:1101-1110.
72. Wu X., Lu C., Ye Y., et al. Germline genetic variations in drug action pathways predict clinical outcomes in advanced lung cancer treated with platinum-based chemotherapy. Pharmacogenet Genomics 2008, 18:955-965.
73. Drummond J.T., Anthoney A., Brown R., Modrich P. Cisplatin and adriamycin resistance are associated with MutLalpha and mismatch repair deficiency in an ovarian tumor cell line. J Biol Chem 1996, 271:19645-19648.
74. Ueda K., Kawashima H., Ohtani S., et al. The 3p21.3 tumor suppressor NPRL2 plays an important role in cisplatin-induced resistance in human non-small-cell lung cancer cells. Cancer Res 2006, 66:9682-9690.
75. Marsit C.J., Hasegawa M., Hirao T., et al. Loss of heterozygosity of chromosome 3p21 is associated with mutant TP53 and better patient survival in non-small-cell lung cancer. Cancer Res 2004, 64:8702-8707.
76. Wang Y.C., Lu Y.P., Tseng R.C., et al. Inactivation of hMLH1 and hMSH2 by promoter methylation in primary non-small cell lung tumors and matched sputum samples. J Clin Invest 2003, 111:887-895.
77. Hsu H.S., Wen C.K., Tang Y.A., et al. Promoter hypermethylation is the predominant mechanism in hMLH1 and hMSH2 deregulation and is a poor prognostic factor in nonsmoking lung cancer. Clin Cancer Res 2005, 11:5410-5416.
78. Katayama H., Wang J., Treekitkarnmongkol W., et al. Aurora kinase-A inactivates DNA damage-induced apoptosis and spindle assembly checkpoint response functions of p73. Cancer Cell 2012, 21:196-211.
79. Michels J., Vitale I., Galluzzi L., et al. Cisplatin resistance associated with PARP hyperactivation. Cancer Res 2013, 73:2271-2280.
80. Olaussen K.A., Adam J., Vanhecke E., et al. PARP1 impact on DNA repair of platinum adducts: preclinical and clinical readouts. Lung Cancer 2013, 80:216-222.
81. Shin D.H., Choi Y.J., Park J.W. SIRT1 and AMPK mediate hypoxia-induced resistance of non-small cell lung cancers to cisplatin and doxorubicin. Cancer Res 2014, 74:298-308.
82. Wu D.W., Wu T.C., Wu J.Y., et al. Phosphorylation of paxillin confers cisplatin resistance in non-small cell lung cancer via activating ERK-mediated Bcl-2 expression. Oncogene 2014, 33(35):4385-4395. 10.1038/onc.2013.389.
83. Sherman-Baust C.A., Weeraratna A.T., Rangel L.B., et al. Remodeling of the extracellular matrix through overexpression of collagen VI contributes to cisplatin resistance in ovarian cancer cells. Cancer cell 2003, 3:377-386.
84. Park J., Morley T.S., Scherer P.E. Inhibition of endotrophin, a cleavage product of collagen VI, confers cisplatin sensitivity to tumours. EMBO Mol Med 2013, 5:935-948.
85. Bertolini G., Roz L., Perego P., et al. Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment. Proc Natl Acad Sci USA 2009, 106:16281-16286.
86. Barr M.P., Gray S.G., Hoffmann A.C., et al. Generation and characterisation of cisplatin-resistant non-small cell lung cancer cell lines displaying a stem-like signature. PLoS One 2013, 8(1):e54193.
87. Farber-Katz S.E., Dippold H.C., Buschman M.D., et al. DNA damage triggers golgi dispersal via DNA-PK and GOLPH3. Cell 2014, 156:413-427.
88. Petrelli F., Coinu A., Cabiddu M., Ghilardi M., Ardine M., Barni S. Platinum rechallenge in patients with advanced NSCLC: a pooled analysis. Lung Cancer 2013, 81:337-342.
89. Birkelbach M., Ferraiolo N., Gheorghiu L., et al. Detection of impaired homologous recombination repair in NSCLC cells and tissues. J Thorac Oncol 2013, 8:279-286.
90. Papadaki C., Sfakianaki M., Ioannidis G., et al. ERCC1 and BRAC1 mRNA expression levels in the primary tumor could predict the effectiveness of the second-line cisplatin-based chemotherapy in pretreated patients with metastatic non-small cell lung cancer. J Thorac Oncol 2012, 7:663-671.
91. Lee S.Y., Kang H.G., Yoo S.S., et al. Polymorphisms in DNA repair and apoptosis-related genes and clinical outcomes of patients with non-small cell lung cancer treated with first-line paclitaxel-cisplatin chemotherapy. Lung Cancer 2013, 82:330-339.
92. Paul I., Savage K.I., Blayney J.K., et al. PARP inhibition induces BAX/BAK-independent synthetic lethality of BRCA1-deficient non-small cell lung cancer. J Pathol 2011, 224:564-574.
93. Fuertes M.A., Castilla J., Alonso C., Pérez J.M. Novel concepts in the development of platinum antitumour drugs. Curr Med Chem Anticancer Agents 2002, 2:539-551.
94. Edelman M.J., Watson D., Wang X., et al. Eicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapy-Cancer and Leukemia Group B Trial 30203. J Clin Oncol 2008, 26(6):848-855.
95. Holford J., Sharp S.Y., Murrer B.A., Abrams M., Kelland L.R. In vitro circumvention of cisplatin resistance by the novel sterically hindered platinum complex AMD473. Br J Cancer 1998, 77:366-373.
96. Holford J., Beale P.J., Boxall F.E., Sharp S.Y., Kelland L.R. Mechanisms of drug resistance to the platinum complex ZD0473 in ovarian cancer cell lines. Eur J Cancer 2000, 36:1984-1990.
97. Shukuya T, Yamanaka T, Seto T, et al. Nedaplatin plus docetaxel for advanced or relapsed squamous cell carcinoma of the lung (WJOG5208L): a randomised, open-label, phase 3 trial. Lancet Oncology 2015 Oct 27. PubMed PMID: 26522337. ([S1470-2045(15)00305-8 [pii]]). Epub 2015 Sep 27. doi:10.1016/S1470-2045(15)00305-8.
98. Ruckdeschel J.C., Finkelstein D.M., Ettinger D.S., et al. A randomized trial of the four most active regimens for metastatic non-small-cell lung cancer. J Clin Oncol 1986, 4:14-22.
99. Bonomi P.D., Finkelstein D.M., Ruckdeschel J.C., et al. Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small-cell lung cancer: a study of the Eastern Cooperative Oncology Group. J Clin Oncol 1989, 7:1602-1613.
100. Weick J.K., Crowley J., Natale R.B., et al. A randomized trial of five cisplatin-containing treatments in patients with metastatic non-small-cell lung cancer: a Southwest Oncology Group study. J Clin Oncol 1991, 9:1157-1162.
101. Seynaeve C., Verweij J., de Mulder P.H. HT3 receptor antagonists, a new approach in emesis: a review of ondansetron, granisetron and tropisetron. Anticancer Drugs 1991, 2:343-355.
102. Bonomi P., Kim K., Kusler J., Johnson D. Cisplatin/etoposide vs paclitaxel/cisplatin/G-CSF vs paclitaxel/cisplatin in non-small-cell lung cancer. Oncology (Williston Park) 1997, 11(4 Suppl 3):9-10.
103. Muraki K., Koyama R., Honma Y., et al. Hydration with magnesium and mannitol without furosemide prevents the nephrotoxicity induced by cisplatin and pemetrexed in patients with advanced non-small cell lung cancer. J Thorac Dis 2012, 4:562-568.
104. Giaccone G., Herbst R.S., Manegold C., et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 1. J Clin Oncol 2004, 22:777-784.
105. Herbst R.S., Giaccone G., Schiller J.H., et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 2. J Clin Oncol 2004, 22(5):785-794.
106. Herbst R.S., Prager D., Hermann R., et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2005, 23(25):5892-5899.
107. Gatzemeier U., Pluzanska A., Szczesna A., et al. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. J Clin Oncol 2007, 25(12):1545-1552.
108. Mok T.S., Wu Y.L., Yu C.J., et al. Randomized, placebo-controlled, phase II study of sequential erlotinib and chemotherapy as first-line treatment for advanced non-small-cell lung cancer. J Clin Oncol 2009, 27(30):5080-5087.
109. Lynch T.J., Patel T., Dreisbach L., et al. Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099. J Clin Oncol 2010, 28:911-917.
110. Lee S.M., Rudd R., Woll P.J., et al. Randomized double-blind placebo-controlled trial of thalidomide in combination with gemcitabine and Carboplatin in advanced non-small-cell lung cancer. J Clin Oncol 2009, 27(31):5248-5254.
111. Heymach J.V., Paz-Ares L., De Braud F., et al. Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer. J Clin Oncol 2008, 26(33):5407-5415.
112. Scagliotti G., Novello S., von Pawel J., et al. Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer. J Clin Oncol 2010, 28:1835-1842.
113. Paz-Ares L.G., Biesma B., Heigener D., et al. Phase III, randomized, double-blind, placebo-controlled trial of gemcitabine/cisplatin alone or with sorafenib for the first-line treatment of advanced, nonsquamous non-small-cell lung cancer. J Clin Oncol 2012, 30(25):3084-3092.
114. Bissett D., O'Byrne K.J., von Pawel J., et al. Phase III study of matrix metalloproteinase inhibitor prinomastat in non-small-cell lung cancer. J Clin Oncol 2005, 23:842-849.
115. Leighl N.B., Paz-Ares L., Douillard J.Y., et al. Randomized phase III study of matrix metalloproteinase inhibitor BMS-275291 in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: National Cancer Institute of Canada-Clinical Trials Group Study BR.18. J Clin Oncol 2005, 23:2831-2839.
116. Laurie S.A., Solomon B.J., Seymour L., et al. Randomised, double-blind trial of carboplatin and paclitaxel with daily oral cediranib or placebo in patients with advanced non-small cell lung cancer: NCIC Clinical Trials Group study BR29. Eur J Cancer 2014, 50(4):706-712.
117. Dy G.K., Mandrekar S.J., Nelson G.D., et al. A randomized phase II study of gemcitabine and carboplatin with or without cediranib as first-line therapy in advanced non-small-cell lung cancer: North Central Cancer Treatment Group Study N0528. J Thorac Oncol 2013, 8(1):79-88.
118. Langer C.J., Novello S., Park K., et al. Randomized, phase III trial of first-line figitumumab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin alone in patients with advanced non-small-cell lung cancer. J Clin Oncol 2014, 32(19):2059-2066.
119. Paz-Ares L., Douillard J.Y., Koralewski P., et al. Phase III study of gemcitabine and cisplatin with or without aprinocarsen, a protein kinase C-alpha antisense oligonucleotide, in patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2006, 24:1428-1434.
120. Ridolfi L., Bertetto O., Santo A., et al. Chemotherapy with or without low-dose interleukin-2 in advanced non-small cell lung cancer: results from a phase III randomized multicentric trial. Int J Oncol 2011, 39:1011-1017.
121. Hirsh V., Paz-Ares L., Boyer M., et al. Randomized phase III trial of paclitaxel/carboplatin with or without PF-3512676 (Toll-like receptor 9 agonist) as first-line treatment for advanced non-small-cell lung cancer. J Clin Oncol 2011, 29:2667-2674.
122. Manegold C., Gravenor D., Woytowitz D., et al. Randomized phase II trial of a toll-like receptor 9 agonist oligodeoxynucleotide, PF-3512676, in combination with first-line taxane plus platinum chemotherapy for advanced-stage non-small-cell lung cancer. J Clin Oncol 2008, 26:3979-3986.
123. Groen H.J., Sietsma H., Vincent A., et al. Randomized, placebo-controlled phase III study of docetaxel plus carboplatin with celecoxib and cyclooxygenase-2 expression as a biomarker for patients with advanced non-small-cell lung cancer: the NVALT-4 study. J Clin Oncol 2011, 29:4320-4326.
124. Blumenschein G., Ludwig C., Thomas G., et al. O-082 A randomized phase III trial comparing ionafarnib/carboplatin/paclitaxel versus carboplatin/paclitaxel (CP) in chemotherapy-naive patients with advanced or metastatic non-small cell lung cancer (NSCLC). Lung Cancer 2005, 49(2):S30. Abstract O-082.
125. Ramlau R., Zatloukal P., Jassem J., et al. Randomized phase III trial comparing bexarotene (L1069-49)/cisplatin/vinorelbine with cisplatin/vinorelbine in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer: SPIRIT I. J Clin Oncol 2008, 26:1886-1892.